Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Whole genome sequencing of Kazachstania humilis and Kazachstania bulderi

PROVIDER: PRJEB44438 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
		Other
	ERR5775463_1.fastq.gz	Fastqsanger.gz
	ERR5775463_2.fastq.gz	Fastqsanger.gz
	ERR5775464_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Unveiling the genetic basis of the low pH response in the acidophilic yeast Maudiozyma bulderi (previously Kazachstania bulderi) via transcriptomic analysis

Project description:Non-conventional yeasts represent a great genetic and phenotypic diversity with potential for industrial strain development in the bio-production of green chemicals. In recent years, mass genome sequencing of non-conventional yeasts has opened avenues to improved understanding of transcriptional networks and phenotypic plasticity and gene function, including the discovery of novel genes. Here, we investigated the gene expression changes at low-pH in three strains of the acidophilic yeast Maudiozyma bulderi (previously Kazachstania bulderi): CBS8638, CBS8639 and NRRL-Y27205. The comparison of the transcriptome of cells growing in a bioreactor at pH=5.5 vs pH= 2.5, primarily showed dysregulation of genes involved in cell wall integrity, with NRRL-Y27205, the least acidophilic strain, showing the largest transcriptional response when compared to the other two strains. We identified four uncharacterised genes, unique to M. bulderi ,and predicted function as transporters, upregulated at low pH. We also showed that M. bulderi cell wall and membrane lipid composition is not significantly affected by low pH unlike Saccharomyces cerevisiae. Overall, our data on transcriptional variability in M. bulderi highlights genes and cellular pathways involved in the acidophilic adaptation of this species and can aid further strain development.

2025-10-22 | E-MTAB-15136 | biostudies-arrayexpress

Project description:Kazachstania bulderi genome assembly

| PRJNA929900 | ENA

Maudiozyma humilis

Project description:Kazachstania humilis overview

| PRJNA768519 | ENA

Maudiozyma humilis strain:MAW1

Project description:Kazachstania humilis MAW1 genome sequencing and assembly

| PRJNA785806 | ENA

Maudiozyma humilis strain:YMX000554

Project description:Draft genome sequences of Kazachstania humilis YMX000554

| PRJNA765336 | ENA

Maudiozyma humilis strain:YMX004033

Project description:Draft genome sequence of Kazachstania humilis YMX004033

| PRJNA765343 | ENA

Maudiozyma humilis strain:YMX003162

Project description:Draft genome sequence of Kazachstania humilis YMX003162

| PRJNA765342 | ENA

Maudiozyma humilis strain:YMX000387

Project description:Draft genome sequences of Kazachstania humilis YMX000387

| PRJNA765338 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

Project description:Shotgun metagenomic sequencing of strong-flavor Baijiu fermentation with Kazachstania bulderi FJ1-3 inoculation

| PRJNA1449785 | ENA